Quick Reports
COVID-19 Pneumonia in a Psoriasis Patient during Secukinumab Treatment
2020 Volume 130 Issue 13 Pages 2699-2703
Details
2020 Volume 130 Issue 13 Pages 2699-2703
A 58-year-old patient developed psoriasis when he was 53. He has COPD. He had smoked 20 cigarettes/day from the age of 20 to 52 and 10 electronic cigarettes/day (iQOS®) from the age of 53. He was administrated secukinumab (SEC) for his psoriasis, which was improved by the treatment; he was maintaining PASI clear. In March 2020, he developed COVID-19 pneumonia and was prescribed hydroxychloroquine 400 mg/day for COVID-19 pneumonia with discontinuation of SEC. The COVID-19 pneumonia was ameliorated. He has maintained his improved condition without SEC treatment for 3 month to date.
